Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...